New perspectives in occult hepatitis C virus infection

World Journal of Gastroenterology

Volumn 18, Issue 23, 2012, Pages 2887-2894

  Carreño, Vicente ^a   Bartolomé, Javier ^a   Castillo, Inmaculada ^a   Quiroga, Juan Antonio ^a  

^a Foundation for the Study of Viral Hepatitis   (Spain)

Author keywords

Hepatitis C virus RNA; Liver; Occult hepatitis C virus; Peripheral blood mononuclear cells; T cell

Indexed keywords

HEPATITIS C ANTIGEN; LIVER ENZYME; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

BLOOD DONOR; CHRONIC HEPATITIS; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LIVER; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NONHUMAN; OCCULT HEPATITIS C; OCCULT INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TREATMENT RESPONSE; VIRION; VIRUS DETECTION; VIRUS HEPATITIS; VIRUS REACTIVATION;

EID: 84863109518     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i23.2887     Document Type: Editorial

References (70)

1. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81: 1631-1648
2. Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis 2010; 30: 333-347
3. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63
4. Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010; 36: 91-133
5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567
6. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol 1999; 31 Suppl 1: 17-24
7. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374
8. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, Soussy CJ, Dhumeaux D. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-1702
9. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez-Iñigo E, de Lucas S, Salas C, Jiménez-Heffernan JA, Pérez-Mota A, Graus J, López-Alcorocho JM, Carreño V. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 189: 7-14
10. Radkowski M, Horban A, Gallegos-Orozco JF, Pawelczyk A, Jablonska J, Wilkinson J, Adair D, Laskus T. Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels. J Infect Dis 2005; 191: 1730-1733
11. Falcón V, Acosta-Rivero N, Shibayama M, Luna-Munoz J, Miranda-Sanchez M, de la Rosa MC, Menéndez I, Gra B, Dueñas-Carrera S, García W, Vilar E, Silva J, Lopez D, González-Bravo M, Fernández-Ortega C, Casillas D, Morales J, Kouri J, Tsutsumi V. Evidences of hepatitis C virus replication in hepatocytes and peripheral blood mononuclear cells from patients negative for viral RNA in serum. Am J Infect Dis 2005; 1: 34-42
12. Carreño V, Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Bartolomé J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibodypositive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J Infect Dis 2006; 194: 53-60
13. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78: 5867-5874
14. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-114
15. Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bartolomé J, Carreño V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006; 43: 1277-1283
16. Pham TN, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalak TI. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat 2012; 19: 103-111
17. Castillo I, Rodríguez-Iñigo E, Bartolomé J, de Lucas S, Ortíz-Movilla N, López-Alcorocho JM, Pardo M, Carreño V. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005; 54: 682-685
18. Esaki T, Suzuki N, Yokoyama K, Iwata K, Irie M, Anan A, Nakane H, Yoshikane M, Nishizawa S, Ueda S, Sohda T, Watanabe H, Sakisaka S. Hepatocellular carcinoma in a patient with liver cirrhosis associated with negative serum HCV tests but positive liver tissue HCV RNA. Intern Med 2004; 43: 279-282
19. Comar M, Dal Molin G, D'Agaro P, Crocè SL, Tiribelli C, Campello C. HBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. J Clin Pathol 2006; 59: 526-529
20. Zaghloul H, El-Sherbiny W. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest 2010; 39: 284-291
21. Cortés-Mancera FM, Restrepo JC, Osorio G, Hoyos S, Correa G, Navas MC. Occult hepatitis C virus infection in a retransplanted patients with liver failure of unknown etiology. Rev Col Gastroenterol 2010; 25: 72-80
22. Idrees M, Lal A, Malik FA, Hussain A, Rehman I, Akbar H, Butt S, Ali M, Ali L, Malik FA. Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infect Genet Evol 2011; 11: 442-445
23. Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Madjd Z, Toosi MN, Alizadeh AH. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol 2011; 83: 989-995
24. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernández N, González-Parra E, Alcazar JM, Sánchez C, Diez-Baylón JC, Martinez P, Bartolomé J, Carreño V. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008; 19: 2288-2292
25. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Hepatitis C virus infection in the family setting of patients with occult hepatitis C. J Med Virol 2009; 81: 1198-1203
26. De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Merletti F, Richiardi L, Sacerdote C. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS One 2009; 4: e8128
27. Bartolomé J, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Quiroga JA, Palacios R, Carreño V. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007; 81: 7710-7715
28. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006; 80: 2418-2428
29. Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, Pardo M, Carreño V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 2006; 80: 10972-10979
30. Carreño V, Bartolomé J, Castillo I, Quiroga JA. Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 2008; 18: 139-157
31. Rico MA, Ruiz S, Subirá D, Barril G, Cigarrán S, Castañón S, Quiroga JA, Selgas R, Carreño V. Virus-specific effector CD4+ T-cell responses in hemodialysis patients with hepatitis C virus infection. J Med Virol 2004; 72: 66-74
32. Pham TN, Coffin CS, Michalak TI. Occult hepatitis C virus infection: what does it mean? Liver Int 2010; 30: 502-511
33. Pham TN, Mercer SE, Michalak TI. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat 2009; 16: 547-556
34. Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Carreño V. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. J Med Virol 2006; 78: 1190-1197
35. Barril G, Quiroga JA, Espinosa M, Arenas D, García-Valdecasas J, González-Parra E, García-Fernández N, Alcazar JN, Sánchez-González MC, Martínez-Rubio P, Llorente S, Castillo I, Bartolomé J, Carreño V. Hepatitis C virus (HCV)-specific T-cell responses are often detectable among hemodialysis patients at risk of occult HCV infection. Clinical Kideney Journal 2009; 2 (suppl 2): 1353
36. Quiroga JA, Llorente S, Castillo I, Bartolome J, Barril G, Carreño V. Tracking intrafamilial spread of serologically silent occult HCV infection through humoral and cellular HCVspecific responses. J Hepatol 2009; 50; S149
37. Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 2011; 140: 676-685+e1
38. Quiroga JA, Castillo I, Pardo M, Rodríguez-Iñigo E, Carreño V. Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection. J Clin Microbiol 2006; 44: 4559-4560
39. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-582
40. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kuzuya T, Honda T, Hayashi K, Nakano I, Katano Y, Goto H. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy. Clin Infect Dis 2005; 40: e49-e54
41. Umemura T, Wang RY, Schechterly C, Shih JW, Kiyosawa K, Alter HJ. Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 2006; 43: 91-99
42. Semmo N, Barnes E, Taylor C, Kurtz J, Harcourt G, Smith N, Klenerman P. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 2005; 365: 327-329
43. Echevarría JM, Avellón A, Jonas G, Hausmann M, Vockel A, Kapprell HP. Sensitivity of a modified version of the ARCHITECT Anti-HCV test in detecting samples with immunoblot-confirmed, low-level antibody to hepatitis C virus. J Clin Virol 2006; 35: 368-372
44. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, Haber PS, Marinos G, Levy MH, Kaldor JM, Dolan KA, Ffrench RA, Lloyd AR, Rawlinson WD. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189: 1846-1855
45. Quiroga JA, Castillo I, Llorente S, Bartolomé J, Barril G, Carreño V. Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope. J Hepatol 2009; 50: 256-263
46. Lodrini S, Bagaglio S, Canducci F, De Mitri MS, Andreone P, Loggi E, Lazzarin A, Clementi M, Morsica G. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. J Biol Regul Homeost Agents 2003; 17: 198-204
47. Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 1994; 91: 8239-8243
48. Pham TN, Mulrooney-Cousins PM, Mercer SE, MacParland SA, Inglot M, Zalewska M, Simon K, Michalak TI. Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells during persistent occult infection. J Viral Hepat 2007; 14: 537-548
49. Kubitschke A, Bahr MJ, Aslan N, Bader C, Tillmann HL, Sarrazin C, Greten T, Wiegand J, Manns MP, Wedemeyer H. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest 2007; 37: 54-64
50. Freeman AJ, Ffrench RA, Post JJ, Harvey CE, Gilmour SJ, White PA, Marinos G, van Beek I, Rawlinson WD, Lloyd AR. Prevalence of production of virus-specific interferongamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 2004; 190: 1093-1097
51. Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler-Normann C, Tobler LH, Busch MP, Carrington M, McKeating JA, O'Brien TR, Rehermann B. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008; 198: 203-212
52. Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, Talal AH, Edlin BR. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009; 16: 10-20
53. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol 2010; 82: 1554-1559
54. Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Castillo I, Carreño V. Comparative study between occult hepatitis C virus infection and chronic hepatitis C. J Viral Hepat 2007; 14: 36-40
55. Pardo M, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Perez-Mota A, Carreño V. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther 2006; 23: 1153-1159
56. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432
57. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
58. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-961
59. Alberti A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 2011; 31 Suppl 1: 18-22
60. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int 2011; 31: 1519-1524
61. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection. Aliment Pharmacol Ther 2009; 30: 477-486
62. Basaras M, Lombera N, de las Heras B, López C, Arrese E, Cisterna R. Distribution of HCV genotypes in patients infected by different sources. Res Virol 1997; 148: 367-373
63. Ramos B, Núñez M, Toro C, Sheldon J, García-Samaniego J, Ríos P, Soriano V. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIVcoinfected patients. J Infect 2007; 54: 173-179
64. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3: 333-340
65. Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol) 2004; 16: 204-205
66. Zekri AR, Mohamed WS, Samra MA, Sherif GM, El-Shehaby AM, El-Sayed MH. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 2004; 13: 305-311
67. Melon S, Galarraga MC, Villar M, Laures A, Boga JA, de Oña M, Gomez E. Hepatitis C virus reactivation in anti-hepatitic C virus-positive renal transplant recipients. Transplant Proc 2005; 37: 2083-2085
68. Lee WM, Polson JE, Carney DS, Sahin B, Gale M. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis 2005; 192: 1088-1092
69. Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 2008; 80: 1720-1722
70. Kopko PM, Holland PV. Universal leukocyte reduction. Curr Opin Hematol 2000; 7: 397-401